Please note. Investigational: not approved by the FDA. Information is for clinical and research awareness only. Not a recommendation to use.
No perspectives yet — be the first!
Be the first verified clinician to share a view on Retatrutide.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
Retatrutide is a novel triple agonist peptide at the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor.
Retatrutide
Not approved by the FDA. Being tested in clinical trials (furthest: Phase 3).
Tested in at least one proper controlled study in people, with results.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Tested in at least one proper controlled study in people, with results.
Not FDA-approved. In clinical trials (highest phase: Phase 3); 19 trial(s) listed on ClinicalTrials.gov, led by Eli Lilly and Company, Hudson Biotech.
Last verified: Nov 11, 2026
Share your pre-launch perspective on Retatrutide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
